Kyung-Hyo Do, Jae-Won Byun, Wan-Kyu Lee
Department of Veterinary Bacteriology and Infectious Diseases, College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea.
Animal Disease Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon 39660, Korea.
Antibiotics (Basel). 2020 Oct 29;9(11):755. doi: 10.3390/antibiotics9110755.
This study aimed to survey the antimicrobial resistance profiles of 690 pathogenic Escherichia coli isolates obtained from Korean pigs with symptoms of enteric colibacillosis between 2007 and 2017, while assessing the change in antimicrobial resistance profiles before and after the ban on antibiotic growth promoters (AGPs). Following the Clinical and Laboratory Standards Institute guidelines, the antimicrobial resistance phenotype was analyzed through the disk diffusion method, and the genotype was analyzed by the polymerase chain reaction. After the ban on AGPs, resistance to gentamicin (from 68.8% to 39.0%), neomycin (from 84.9% to 57.8%), ciprofloxacin (from 49.5% to 39.6%), norfloxacin (from 46.8% to 37.3%), and amoxicillin/clavulanic acid (from 40.8% to 23.5%) decreased compared to before the ban. However, resistance to cephalothin (from 51.4% to 66.5%), cefepime (from 0.0% to 2.4%), and colistin (from 7.3% to 11.0%) had increased. We confirmed a high percentage of multidrug resistance before (95.0%) and after (96.6%) the ban on AGPs. The AmpC gene was the most prevalent from 2007 to 2017 (60.0%), followed by the blaTEM gene (55.5%). The blaTEM was prevalent before (2007-2011, 69.3%) and after (2012-2017, 49.2%) the ban on AGPs. These results provide data that can be used for the prevention and treatment of enteric colibacillosis.
本研究旨在调查2007年至2017年间从患有肠道大肠杆菌病症状的韩国猪中分离出的690株致病性大肠杆菌的抗菌药物耐药谱,同时评估抗生素生长促进剂(AGPs)禁令前后抗菌药物耐药谱的变化。按照临床和实验室标准协会的指南,通过纸片扩散法分析抗菌药物耐药表型,并通过聚合酶链反应分析基因型。AGPs禁令实施后,与禁令前相比,对庆大霉素(从68.8%降至39.0%)、新霉素(从84.9%降至57.8%)、环丙沙星(从49.5%降至39.6%)、诺氟沙星(从46.8%降至37.3%)和阿莫西林/克拉维酸(从40.8%降至23.5%)的耐药性有所下降。然而,对头孢噻吩(从51.4%升至66.5%)、头孢吡肟(从0.0%升至2.4%)和黏菌素(从7.3%升至11.0%)的耐药性有所增加。我们证实,AGPs禁令前后多药耐药率都很高(禁令前为95.0%,禁令后为96.6%)。2007年至2017年,AmpC基因最为普遍(60.0%),其次是blaTEM基因(55.5%)。AGPs禁令实施前(2007 - 2011年,69.3%)和实施后(2012 - 2017年,49.2%),blaTEM基因都很普遍。这些结果为肠道大肠杆菌病的预防和治疗提供了可用数据。